Cargando…

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial

Background and purpose — The ENLIVEN trial showed that, after 25 weeks, pexidartinib statistically significantly reduced tumor size more than placebo in patients with symptomatic, advanced tenosynovial giant cell tumor (TGCT) for whom surgery was not recommended. Here, we detail the effect of pexida...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van De Sande, Michiel, Tap, William D, Gelhorn, Heather L, Ye, Xin, Speck, Rebecca M, Palmerini, Emanuela, Stacchiotti, Silvia, Desai, Jayesh, Wagner, Andrew J, Alcindor, Thierry, Ganjoo, Kristen, Martín-Broto, Javier, Wang, Qiang, Shuster, Dale, Gelderblom, Hans, Healey, John H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382018/ https://www.ncbi.nlm.nih.gov/pubmed/33977825 http://dx.doi.org/10.1080/17453674.2021.1922161

Ejemplares similares

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors
por: Gelderblom, Hans, et al.
Publicado: (2020)

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
por: Yin, Ophelia, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors
por: Lewis, James H., et al.
Publicado: (2020)

Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations
por: Vaynrub, Anna, et al.
Publicado: (2022)

Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies
por: Palmerini, Emanuela, et al.
Publicado: (2023)

Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
por: Monestime, Shanada, et al.
Publicado: (2020)

Why Not Enliven the Annual Meeting?
Publicado: (1906)

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study
por: Bernthal, Nicholas M., et al.
Publicado: (2021)

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease
por: Healey, John H., et al.
Publicado: (2020)

Psychometric properties of a custom Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form and worst stiffness numeric rating scale in tenosynovial giant cell tumors
por: Speck, Rebecca M., et al.
Publicado: (2020)

Patient-reported Symptoms of Tenosynovial Giant Cell Tumors
por: Gelhorn, Heather L., et al.
Publicado: (2016)

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
por: Zahir, Hamim, et al.
Publicado: (2022)

Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature
por: Giustini, Nicholas, et al.
Publicado: (2018)

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics
por: Zahir, Hamim, et al.
Publicado: (2022)

The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS)
por: Gelhorn, Heather L., et al.
Publicado: (2019)

New structure enlivens interest in P2X receptors
por: Browne, Liam E., et al.
Publicado: (2010)

Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases
por: Mastboom, Monique J. L., et al.
Publicado: (2017)

Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2019)

Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis
por: Thongchot, Suyanee, et al.
Publicado: (2022)

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
por: Verspoor, F. G. M., et al.
Publicado: (2019)

Correction to: Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2020)

MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment
por: Spierenburg, Geert, et al.
Publicado: (2023)

Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
por: Benner, Brooke, et al.
Publicado: (2020)

Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
por: van IJzendoorn, David G.P., et al.
Publicado: (2022)

A novel colony‐stimulating factor 1 (CSF1) translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor
por: Lipplaa, Astrid, et al.
Publicado: (2023)

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
por: Tap, William D., et al.
Publicado: (2022)

Nursing Students Explore Meaningful Activities for Nursing Home Residents: Enlivening the Residents by Cultivating Their Spark of Life
por: Haugland, Britt Øvrebø, et al.
Publicado: (2021)

The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life
por: Mastboom, Monique Josephine, et al.
Publicado: (2018)

Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands
por: Mastboom, Monique J L, et al.
Publicado: (2017)

Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry
por: Lopez-Bastida, J., et al.
Publicado: (2021)

Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
por: Mastboom, Monique J L, et al.
Publicado: (2018)

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
por: Zahir, Hamim, et al.
Publicado: (2022)

A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor
por: Rosenbaum, Evan, et al.
Publicado: (2019)

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
por: Yang, Jingmei, et al.
Publicado: (2021)

Localized tenosynovial giant cell tumor in children
por: Du, Xifeng, et al.
Publicado: (2023)

Tenosynovial Giant Cell Tumor Arising on the Scapular Region
por: Fukuda, Asako, et al.
Publicado: (2013)

Diffuse Type Tenosynovial Giant Cell Tumor of the Ankle
por: Zhao, Jing-Jing, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cgmta6ogpj6ash7tqcvvpjn5os